When new employees come to work at the Boeing production facility in Everett, Washington, one of their first stops is often an exhibition at the company’s Safety Experience Center. It opens on a sombre note: a memorial for famous air disasters, including the successive crashes of two 737 MAXs, in 2018 and 2019, in the Java Sea and Ethiopia. Then, gradually, the tone grows more hopeful. At Boeing, as throughout the aviation industry, disasters led to innovations. Oxygen masks and electronic anti-skid brakes were introduced in the nineteen-sixties, along with bird cannons at airports, to shoo off Canada geese and fellow-fliers. Overhead bins got latched doors that same decade, to keep luggage from toppling onto passengers’ heads. Satellite communication came along in the seventies; automated flight-management systems, capable of plotting a plane’s course, speed, and altitude, in the eighties. Radar systems got more accurate; planes grew stronger, sleeker, and more flexible. Pilots got better at skirting turbulence—or, if they couldn’t, at slowing down and “riding the bumps.”
Иран установил личности виновных в ударе по школе для девочек в Минабе14:56，更多细节参见PDF资料
Украинцам запретили выступать на Паралимпиаде в форме с картой Украины22:58，推荐阅读PDF资料获取更多信息
Peacock Premium (no free trial)
同时，过去的交易比较集中于肿瘤免疫领域，但如今，交易涉及的病种和技术路径已愈发多元。比如，围绕减重领域的FGF21靶点，去年就接连诞生多笔重磅并购：分别是诺和诺德以52亿美元收购Akero Therapeutics、罗氏以35亿美元收购89Bio，以及GSK以20亿美元收购 Boston Pharmaceuticals。